Ticker

Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) was the recipient of a significant decrease in short interest in the month of August. As of August 14th, there was short interest totaling 760,586 shares, a decrease of 36.4% from the July 30th total of 1,195,547 shares. Based on an average daily trading volume, of 136,177

Prima BioMed Ltd (NASDAQ: IMMP - Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.40 and traded as high as $0.41. Prima BioMed shares last traded at $0.4035, with a volume of 199,287 shares. Analyst Ratings Changes IMMP has been the subject

SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep" or "the Company"), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa ("efti"), has been accepted for presentation at the…

SYDNEY, AUSTRALIA, July 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced a significant positive update of the investigator-initiated INSIGHT-003 Phase I trial evaluating eftilagimod alfa (efti) in combination with MSD's (Merck & Co. Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA®…

LOS ANGELES, July 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Immutep Limited ("Immutep" or "the Company") (NASDAQ: IMMP) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of IMMP during the class period listed are…